Tim Forshew

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8183320/publications.pdf

Version: 2024-02-01

30 papers	7,409 citations	257450 24 h-index	477307 29 g-index
30 all docs	30 docs citations	30 times ranked	12462 citing authors

#	Article	IF	Citations
1	Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. New England Journal of Medicine, 2013, 368, 1199-1209.	27.0	1,884
2	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature, 2013, 497, 108-112.	27.8	1,443
3	Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA. Science Translational Medicine, 2012, 4, 136ra68.	12.4	1,086
4	Mutant p53 Prolongs NF-ÎºB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer. Cancer Cell, 2013, 23, 634-646.	16.8	388
5	Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nature Communications, 2018, 9, 771.	12.8	356
6	Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposisâ€“renal dysfunctionâ€“cholestasis (ARC) syndrome. Nature Genetics, 2004, 36, 400-404.	21.4	313
7	Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nature Genetics, 2014, 46, 837-843.	21.4	302
8	Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. Journal of Pathology, 2009, 218, 172-181.	4.5	270
9	Targeted Therapy for BRAFV600E Malignant Astrocytoma. Clinical Cancer Research, 2011, 17, 7595-7604.	7.0	143
10	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nature Medicine, 2018, 24, 1204-1215.	30.7	133
11	Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS ONE, 2018, 13, e0194630.	2.5	117
12	Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes and Cancer, 2014, 53, 38-51.	2.8	107
13	Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling. PLoS ONE, 2018, 13, e0193802.	2.5	90
14	MAPK pathway activation and the origins of pediatric lowâ€grade astrocytomas. Journal of Cellular Physiology, 2010, 222, 509-514.	4.1	87
15	Locus heterogeneity in autosomal recessive congenital cataracts: linkage to 9q and germline HSF4 mutations. Human Genetics, 2005, 117, 452-459.	3.8	74
16	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). , 2021, 9, e001504.		72
17	MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathologica, 2010, 120, 731-743.	7.7	61
18	RAFgene fusion breakpoints in pediatric brain tumors are characterized by significant enrichment of sequence microhomology. Genome Research, 2011, 21, 505-514.	5.5	61

#	Article	IF	Citations
19	Dynamics of multiple resistance mechanisms in plasma DNA during EGFRâ€targeted therapies in nonâ€small cell lung cancer. EMBO Molecular Medicine, 2018, 10, .	6.9	61
20	MAPK pathway activation in the embryonic pituitary results in stem cell compartment expansion, differentiation defects and provides insights into the pathogenesis of papillary craniopharyngioma. Development (Cambridge), 2017, 144, 2141-2152.	2.5	58
21	Comprehensive molecular characterisation of epilepsy-associated glioneuronal tumours. Acta Neuropathologica, 2018, 135, 115-129.	7.7	57
22	RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathologica, 2010, 120, 271-273.	7.7	49
23	Molecular analysis of pediatric brain tumors identifies microRNAs in pilocytic astrocytomas that target the MAPK and NF-ÎºB pathways. Acta Neuropathologica Communications, 2015, 3, 86.	5.2	40
24	Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)â€”a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. British Journal of Cancer, 2022, 126, 1186-1195.	6.4	32
25	Comparative Expression Analysis Reveals Lineage Relationships between Human and Murine Gliomas and a Dominance of Glial Signatures during Tumor Propagation In Vitro. Cancer Research, 2013, 73, 5834-5844.	0.9	28
26	Reconfiguration of genomic anchors upon transcriptional activation of the human major histocompatibility complex. Genome Research, 2008, 18, 1778-1786.	5.5	26
27	Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. Cancer Medicine, 2017, 6, 2194-2202.	2.8	26
28	Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing. Journal of Molecular Diagnostics, 2015, 17, 521-532.	2.8	25
29	Abstract 3639: Analytical performance and validation of an enhanced TAm-Seq circulating tumor DNA sequencing assay. Cancer Research, 2016, 76, 3639-3639.	0.9	14
30	Replication Timing Profile Reflects the Distinct Functional and Genomic Features of the MHC Class II Region. Cell Cycle, 2007, 6, 2393-2398.	2.6	6